Kirsten rat sarcoma viral oncogene (KRAS) G12C was identified to be a drug target and a predictor of response to the novel AMG510 drug. We showed that KRAS G12C-mutated colorectal cancer has specific clinicopathologic features and worse outcome compared to other KRAS-mutated cases. The knowledge of such distinctive traits of KRAS G12C mutations might be crucial to future translational research studies and clinical trial design.
KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population
Cremolini C.;
2020-01-01
Abstract
Kirsten rat sarcoma viral oncogene (KRAS) G12C was identified to be a drug target and a predictor of response to the novel AMG510 drug. We showed that KRAS G12C-mutated colorectal cancer has specific clinicopathologic features and worse outcome compared to other KRAS-mutated cases. The knowledge of such distinctive traits of KRAS G12C mutations might be crucial to future translational research studies and clinical trial design.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
